[SCHEDULE 13G/A] Immunocore Holdings plc Amended Passive Investment Disclosure
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to a Schedule 13G/A reporting a sizeable passive stake in Immunocore Holdings plc – ADR. As of 12/31/2025, it beneficially owned 5,961,227 ADRs, representing 11.8% of the outstanding class.
The firm reports sole voting and sole dispositive power over all 5,961,227 ADRs, with no shared voting or dispositive power. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunocore.
Positive
- None.
Negative
- None.